OncoMatch/Clinical Trials/NCT04483206
Personalized Autologous Transplant for Multiple Myeloma
Is NCT04483206 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Melphalan for multiple myeloma.
Treatment: Melphalan — This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial uses a new method of dosing that is based on analysis of each individual's blood levels of melphalan after receiving a part of the dose, termed pharmacokinetic analysis. This may help to learn more about how to dose melphalan correctly and which patients are likely to benefit from a personalized dose.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received:
must have received 2+ lines of therapy as defined by the IMWG
Lab requirements
Blood counts
Absolute neutrophil count (ANC) >= 1000/uL; Platelet count >= 100,000
Kidney function
estimated glomerular filtration rate (eGFR) by Cockcroft-Gault > 40 mL/min
Liver function
Total bilirubin < 1.5 x institutional upper limit of normal (unless the patient has an established diagnosis of Gilbert's in which case total bilirubin < 3 mg/dL); AST and ALT < 3 x the institutional upper limit of normal
Cardiac function
Left ventricular ejection fraction >= 45%
Must have estimated glomerular filtration rate (eGFR) by Cockcroft-Gault > 40 mL/min; Absolute neutrophil count (ANC) >= 1000/uL; Platelet count >= 100,000; Total bilirubin < 1.5 x institutional upper limit of normal (unless the patient has an established diagnosis of Gilbert's in which case total bilirubin < 3 mg/dL); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x the institutional upper limit of normal; Left ventricular ejection fraction >= 45%; Diffusion capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in 1 second (FEV1), and forced vital capacity (FVC) > 50% of predicted value (corrected for hemoglobin)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Winship Cancer Institute of Emory University · Atlanta, Georgia
- University Illinois Chicago · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify